COVID-19 Vaccines and Informed Consent
COVID-Period Mass Vaccination Campaign and Public Health Disaster in the USA From age/state-resolved all-cause mortality by time, age-resolved vaccine delivery by time, and socio-geo-economic data
Serious Adverse Events of Special Interest Following mRNA Vaccination in Randomized Trials
Introduction: In 2020, prior to COVID-19 vaccine rollout, the Coalition for Epidemic Preparedness Innovations and Brighton Collaboration created a priority list, endorsed by the World Health Organization, of potential adverse events relevant to COVID-19 vaccines. We leveraged the Brighton Collaboration list to evaluate serious adverse events of special interest observed in phase III randomized trials of mRNA COVID-19 vaccines.
Innate Immune Suppression by SARS-CoV-2 mRNA Vaccinations: The role of G-quadruplexes, exosomes and microRNAs
• mRNA vaccines promote sustained synthesis of the SARS-CoV-2 spike protein.
• The spike protein is neurotoxic, and it impairs DNA repair mechanisms.
• Suppression of type I interferon responses results in impaired innate immunity.
• The mRNA vaccines potentially cause increased risk to infectious diseases and cancer.
• Codon optimization results in G-rich mRNA that has unpredictable complex effects.
Worse Than the Disease? Reviewing Some Possible Unintended Consequences of the mRNA Vaccines Against COVID-19
Immune imprinting, breadth of variant recognition and germinal center response in human SARS-CoV-2 infection and vaccination
• Vaccination confers broader IgG binding of variant RBDs than SARS-CoV-2 infection
• Imprinting from initial antigen exposures alters IgG responses to viral variants
• Histology of mRNA vaccinee lymph nodes shows abundant germinal centers
• Vaccine spike antigen and mRNA persist for weeks in lymph node germinal centers
Anti-nucleocapsid antibodies following SARS-CoV-2 infection in the blinded phase of the mRNA-1273 Covid-19 vaccine efficacy clinical trial
Question: Does prior mRNA-1273 vaccination influence anti-nucleocapsid antibody seroconversion and/or seroreversion after SARS-CoV-2 infection?